-transparent.png){kind=logo}
Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. 2010
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi 835215, India.
3,5-Diaryl pyrazolines analogs were synthesized and evaluated for their monoamine oxidase (MAO) inhibitory activity. The compounds were found reversible and selective towards MAO-A with selectivity index in the magnitude of 10(3)-10(5). The docking studies were carried out to gain further structural insights of the binding mode and possible interactions with the active site of MAO-A. Interestingly, the theoretical (K(i)) values obtained by molecular docking studies were in congruence with their experimental (K(i)) values.
Related Publications
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
January 2010,
Bioorganic & medicinal chemistry letters,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
April 2011,
Bioorganic & medicinal chemistry letters,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
July 2011,
Bioorganic & medicinal chemistry letters,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
March 2015,
European journal of medicinal chemistry,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
October 2021,
Bioorganic chemistry,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
June 2015,
ACS medicinal chemistry letters,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
October 2010,
European journal of medicinal chemistry,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
March 2012,
ChemMedChem,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
September 2014,
Bioorganic & medicinal chemistry letters,
Muthukumar Karuppasamy, and
Manojkumar Mahapatra, and
Samiye Yabanoglu, and
Gulberk Ucar, and
Barij Nayan Sinha, and
Arijit Basu, and
Nibha Mishra, and
Ashoke Sharon, and
Umasankar Kulandaivelu, and
Venkatesan Jayaprakash
December 2008,
Bioorganic & medicinal chemistry letters,
